Who are SEP363856's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SEP-363856.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sep363856.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

SEP363856 — Competitive Intelligence Brief

SEP363856 (SEP363856) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TAAR1 agonist. Area: Psychiatry.

phase 3 TAAR1 agonist TAAR1 (trace amine-associated receptor 1) Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

SEP363856 (SEP363856) — Otsuka Pharmaceutical Development & Commercialization, Inc.. SEP363856 is a trace amine-associated receptor 1 (TAAR1) agonist that modulates glutamatergic and dopaminergic neurotransmission in the brain.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SEP363856 TARGET	SEP363856	Otsuka Pharmaceutical Development & Commercialization, Inc.	phase 3	TAAR1 agonist	TAAR1 (trace amine-associated receptor 1)
SEP-363856	SEP-363856	Otsuka Pharmaceutical Development & Commercialization, Inc.	phase 3	TAAR1 agonist	TAAR1 (trace amine-associated receptor 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TAAR1 agonist class)

Otsuka Pharmaceutical Development & Commercialization, Inc. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SEP363856 — Competitive Intelligence Brief. https://druglandscape.com/ci/sep363856. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab